Nuvation Bio Inc. (NUVB) Stock Analysis
A live, multi-source view of Nuvation Bio Inc. (NUVB): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Sector: Healthcare · Industry: Biotechnology · United States · 305 employees · nuvationbio.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Nuvation Bio Inc. (NUVB) had a market capitalization of $2.39B (forward -454.0) and a beta of 1.53; the shares traded in a 52-week range of $2.99 – $9.75 (95.1% over the year).
- Market cap
- $2.39B
- Enterprise value
- $2.15B
- Forward P/E
- -454.0
- Price / book
- 9.38
- EPS (trailing)
- $-0.44
- EPS (forward)
- $-0.01
- Payout ratio
- 0.0%
- 52-week range
- $2.99 – $9.75
- 52-week change
- 95.1%
- Beta
- 1.53
- Average volume
- 6.8M
- Shares outstanding
- 350.1M
- Short % of float
- 24.96%
- Profit margin
- -88.2%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Nuvation Bio Inc. (NUVB) last closed at $6.28 (the last completed close before that scan).
Technicals at the scan: RSI 43 (neutral territory), price -6.5% versus its 20-day average, 20-day versus 50-day average spread +5.0%, MACD histogram -0.08.
Sentiment inputs: 100% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 80/100.
Next scheduled company event: in 52 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of NUVB; corporate insiders filed 0 buys and 1 sell (1 filer, latest disclosure 2026-08-21). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Gary Hattersley (0B/1S). Who is trading what
RapidTradeView pick record
NUVB has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Nuvation Bio Inc. (NUVB) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell NUVB.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.